Medicover AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 43.22.
Medicover AB's Days Inventory for the
three
months ended in Mar. 2026 was 12.8.
Medicover AB's Days Payable for the
three
months ended in Mar. 2026 was 39.71.
Therefore, Medicover AB's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 16.31.
Medicover AB (LTS:0RPS) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Medicover AB Cash Conversion Cycle Related Terms
Medicover AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Medicover AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RPS vs HCA, THC, DVA: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, Medicover AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicover AB Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medicover AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Medicover AB's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Medicover AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicover AB (LTS:0RPS) has a Cash Conversion Cycle of 16.31 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medicover AB and its competitors.
Is Medicover AB's Cash Conversion Cycle too high?
Medicover AB's current Cash Conversion Cycle is 16.31. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.10. Medicover AB's value of 16.31 is 9.9% below this industry median. Overall, Medicover AB has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medicover AB's Cash Conversion Cycle compare to HCA and THC?
Medicover AB's Cash Conversion Cycle of 16.31 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.10. Medicover AB's value of 16.31 is 9.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.10, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicover AB's current Cash Conversion Cycle of 16.31 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medicover AB and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicover AB's current Cash Conversion Cycle is 16.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicover AB stock overvalued right now?
Based on GuruFocus' analysis, Medicover AB (LTS:0RPS) is currently considered Fairly Valued. The stock's GF Value™ is kr234.40, compared to a current price of kr238.00 — trading 1.5% above its estimated fair value. The current Cash Conversion Cycle is 16.31 and 9.9% below the Healthcare Providers & Services industry median of 18.10. Medicover AB's overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Medicover AB (LTS:0RPS), the current Cash Conversion Cycle is 16.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicover AB (LTS:0RPS) Overvalued in 2026?
Based on GuruFocus' analysis, Medicover AB stock appears to be overvalued.
The current stock price of kr238.00 is trading 1.5% above its estimated GF Value™ of kr234.40.
GuruFocus considers Medicover AB to be Fairly Valued.
Key valuation signals for LTS:0RPS:
Cash Conversion Cycle: 16.31
GF Value™: kr234.40 vs. price of kr238.00 (1.5% above fair value)
Industry Position: 9.9% below the Healthcare Providers & Services median
No single metric tells the full story. See the LTS:0RPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicover AB is an international healthcare and diagnostic services provider. It offers a broad spectrum of healthcare services via an extensive network of ambulatory clinics, hospitals, specialty-care facilities, and laboratories. Medicover offers its services through two reportable segments: Healthcare Services, which generates the maximum revenue, and Diagnostic Services. Diagnostic Services offer a broad range of laboratory testing in all clinical pathology areas, and Healthcare Services offer medical care and related services by operating on an Integrated Healthcare and Fee-For-Service model across different countries. Geographically, the company derives maximum revenue from Germany, and the rest from Poland, India, Ukraine, Romania, and other countries.
89GF Score
Get the complete analysis for LTS:0RPS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RPS has been successfully added to your 
